Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 90Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 33Triple Negative Breast Neoplasms 22Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Neoplasm Metastasis 18Ovarian Neoplasms 17Stomach Neoplasms 15Lung Neoplasms 13Head and Neck Neoplasms 11Esophageal Squamous Cell Carcinoma 10Esophageal Neoplasms 10Cholangiocarcinoma 10Recurrence 9Melanoma 8Small Cell Lung Carcinoma 7Sarcoma 7Pancreatic Adenocarcinoma 7Inflammatory Breast Neoplasms 7Breast Neoplasms, Male 7Adenocarcinoma 7Prostatic Neoplasms 6Fallopian Tube Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Uterine Cervical Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4

Interventions

sintilimab 2Cisplatin 2Radiation Dose Hypofractionation 1Radiation 1Platinum 1Irinotecan 1Brachytherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Cervical Carcinoma × Albumin-Bound Paclitaxel × Clear all
NCT06391190 2024-04-30

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

RenJi Hospital

Phase 1/2 Recruiting
20 enrolled
Gynecologic

Locally Advanced Cervical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡